Pharmacy Regulatory Updates 06/13/2026
Heres a quick executive layer to read if one is not inclined to read the whole thing.
Lilly’s June 8 data-submission deadline passed with roughly 1,000 hospitals (led by large DSH systems) still refusing, and GSK has become the 10th manufacturer with an in-house-pharmacy data policy - the enforcement model is spreading, though the actual wholesaler cutoff and any HRSA response remain unconfirmed (Fierce Healthcare; STAT; 340B Report).
HRSA sent its revised 340B Rebate Model Pilot to OMB as a Paperwork Reduction Act collection request publishing June 15, opening a fresh 30-day comment window (closing ~July 15), scope confirmed to the IPAY 2026/2027 negotiated drugs (11 manufacturers), with HRSA holding its 5-hour estimate and parking the substantive objections as “out of scope” - this is not the final step (Federal Register, FR 2026-11989).
Hospitals took two clean 340B wins - HRSA declined to appeal Premier (restoring GPO first-buy flexibility worth millions per hospital per year) and Washington’s SB 5981 took effect June 11 after the court denied the manufacturers’ injunction - though the 1st Circuit heard the Maine/Rhode Island cases June 4 and a Mississippi judge dismissed AbbVie’s challenge, so the trend favors states but is not uniform (340B Report).
UnitedHealthcare’s coordinated oncology squeeze is live: outpatient chemotherapy PA now routes through Optum’s Cancer Guidance Program (June 1), with maintenance/monotherapy site-of-care steerage (Aug 1) and injectable-oncology exclusions (Sept 1) behind it - direct pressure on cancer-infusion margin and 340B capture (UHCprovider.com).
The Section 232 onshoring application deadline passed June 12 with applications confidential and no public applicant list; no new MFN pricing deal signed this period; the next live tripwire is July 31 (large-company / Annex III effective date), the first real pharmaceutical-tariff invoice event (BIS; Federal Register).
The federal 340B apparatus is being reshaped against hospital interests - Trump nominated a Johns Hopkins 340B critic (Ge Bai) as HHS assistant secretary (June 1), and a Schedule P/C civil-service reclassification threatens OPA staffing (340B Report; Reuters).
Section 1 - Federal Regulatory
FDA
Nothing operationally material for the profile in-window. The most recent press announcement remains the June 2 cell-and-gene-therapy draft guidance; nothing newer appeared through June 13. The period’s notable oncology approval - DATROWAY (datopotamab deruxtecan) for triple-negative breast cancer - was dated May 22, just before the window. No change this period from FDA.
CMS
Two material items. First, the operational artifacts for the GLP-1 Bridge dropped June 4 via MLN Connects: CMS released a Prescriber Fact Sheet, a Pharmacy Fact Sheet, and the Prior Authorization Form, plus a pharmacy webinar, ahead of the July 1 start. Configuration details that matter for the Willow build and F6 migration: only 28- or 30-day fills are covered; subsequent fills don’t require new PA unless the patient switches drugs; pharmacies use a specific BIN/PCN; and if the pharmacy doesn’t receive direction, the claim may route to the patient’s Part D plan - the D.0 routing/retention risk to hard-wire before July 1 (CMS).
Second, on June 12 CMS issued a proposed rule on the Medicare Drug Price Negotiation Program, moving it from sub-regulatory guidance into permanent notice-and-comment rulemaking (25 drugs negotiated over two years; MFPs for the first 10 effective January 1, 2026; the Medicare Transaction Facilitator as effectuation infrastructure). This matters because the rebate pilot is scoped to these same negotiated drugs - the negotiation and 340B-rebate tracks are converging (CMS).
Also confirmed on the CMS press page: the June 1 Medicaid community-engagement framework implementing the OBBBA 80-hour work requirements (CMS-2454-IFC), and a June 11 Medicaid 1115 demonstration-spending stewardship action - both carry-forward items.
DEA
DEA published a final rule (FR Doc. 2026-11526) on June 9 implementing the SUPPORT Act’s medication-assisted-treatment provisions, effective July 9, 2026 (Docket DEA-499; Vol. 91, No. 110). The rule eliminates the obsolete DATA-waiver framework and finalizes the conditions under which a pharmacy may deliver Schedule III–V narcotic drugs approved for maintenance or detoxification treatment to a prescribing or administering practitioner’s registered location, per a prescription, for administration by injection or implantation to a named patient (reported 45-day administration window; confirm against the rule text). Read-through: not a 340B or oncology item, but a real compliance/SOP trigger for retail, specialty, ambulatory, and behavioral-health pharmacy teams supporting injectable/implantable MOUD - named-patient documentation, delivery logs, practitioner-receipt and administration-window tracking, and whether the pharmacy system can distinguish clinic-delivered MAT product from ordinary pickup or mail (Federal Register).
HRSA (Office of Pharmacy Affairs)
The headline is the revised 340B Rebate Model Pilot ICR, confirmed against the primary notice (FR Doc. 2026-11989, filed June 12, publishing June 15). The procedural posture corrects secondary commentary: this is not the final regulatory step. It is a Paperwork Reduction Act collection request; OMB may act only after the 30-day comment period closes (~July 15), and a separate Federal Register notice will set the Pilot’s criteria, standards, and data requirements at a future date. Scope is confirmed narrow - the 11 manufacturers holding Medicare Drug Price Negotiation agreements for IPAY 2026 and 2027. HRSA held its burden estimate despite the hospital pushback (it kept 5 hours per response, treating higher FTE-based figures as “overall operational impacts” rather than incremental PRA burden), and - the key tell - explicitly parked the substantive objections (legal authority, cash-flow and acquisition-cost impacts, patient-access harms) as out of scope, “to be addressed in a separate Federal Register notice.” That is the administrative-record-building maneuver the Maine court’s criticism invited. Aggregate burden is estimated at roughly 3.96 million annual covered-entity hours across 15,249 entities reporting weekly (Federal Register).
Route to the 340B analyst queue: HRSA’s Manufacturer Notices feed continues to post refund offers, NDC changes, and ceiling-price recalculations this period (UCB and Eisai refunds, J&J ceiling-price recalculations, Amgen and Baxter NDC changes). These are revenue-cycle hygiene, not strategy, but missed credits, NDC-crosswalk mismatches, and replenishment errors flow from them. HRSA’s decision not to appeal Premier is detailed in Section 4 given its purchasing implications (HRSA).
SCOTUS / Circuit Courts
A busy week, net-favorable to hospitals. Washington’s SB 5981 took effect June 11 after Judge David Estudillo (W.D. Wash.) denied the manufacturers’ injunction June 9; AbbVie appealed to the Ninth Circuit, which has not yet ruled on a state contract-pharmacy law (Section 2). On June 4 the First Circuit heard oral arguments in the Maine and Rhode Island challenges - a decision would be the first appellate ruling in that circuit. A Mississippi federal judge dismissed AbbVie’s challenge to Mississippi’s contract-pharmacy law. The Fourth Circuit en banc rehearing of the West Virginia/Maryland cases shows no change this week; argument/decision still pending (340B Report).
Section 1B - Trade & Tariff Policy (Pharmaceutical)
Onshoring window / BIS. The June 12 application deadline passed. As expected, there is no public outcome: onshoring applications are confidential business submissions reviewed case-by-case, and no applicant list, approved agreement, or Annex III addition has been announced. The benefit ladder is unchanged - an approved onshoring agreement drops the rate from 100% to 20%, and onshoring-plus-MFN to 0% through January 20, 2029. Effective dates, now firmly confirmed: the default 100% tariff takes effect July 31, 2026 for large companies (Annex III) and September 29, 2026 for all others, with generics and their ingredients excluded. Next trigger: July 31, the first real invoice event (BIS; Skadden; Holland & Knight).
Annex IV zero-tariff carve-outs. Beyond the generic/biosimilar carve-out, the proclamation’s Annex IV reportedly exempts several categories directly relevant to this profile - orphan drugs, nuclear medicines / radiopharmaceuticals, plasma-derived therapies, cell and gene therapies, and antibody-drug conjugates. If accurate, that materially narrows exposure on products such as ADCs (e.g., DATROWAY), radiopharmaceuticals (e.g., Pluvicto), and orphan agents.
Generic / biosimilar extension. No change this period. No Commerce signal toward extending Section 232 to generics or biosimilars; the statutory advisory remains due by April 2, 2027.
MFN / CMMI interaction. No new MFN signing this period (the most recent confirmed remains Regeneron, April 23). The week’s relevant move is adjacent, not an MFN deal: the June 12 CMS negotiation rulemaking is the IRA track, distinct from the MFN executive-action track - do not conflate them. No new CMS clarification on GLOBE/GUARD exemptions for MFN signatories.
Adjacent 232 tracks (devices, consumables, PPE, robotics). No change this period. The September 2025 investigations remain open with no public determination - still the standing tripwire for the infusion-pump and disposables supply chain, which does not benefit from 340B.
Litigation. No change. No suit specifically challenging the pharmaceutical tariffs; the February 20 Supreme Court IEEPA ruling left Section 232 intact and reinforced its durability.
Acquisition-cost read-through. Retail and biosimilar lines remain carved out; patented Part B infusion and specialty lines are exposed at 100%, reducible to 20%/0% by company-specific agreement, with country-of-origin rates of 15% (EU, Japan, South Korea, Switzerland/Liechtenstein) and 10% (UK). The 340B ceiling-price formula does not automatically neutralize tariffs; a tariff-embedded cost increase flows to net acquisition cost unless the specific manufacturer secures relief. Nothing becomes a real invoice event until July 31.
Section 2 - State Regulatory (Indiana and Ohio)
Indiana
Three items, two verified to the primary IHCP bulletins.
First, the Medicaid 340B reimbursement cutoff remains set for July 1, and Indiana hospitals are not covered by the FQHC exemption - a DSH hospital is directly exposed; no final FSSA decision, delay, or IHA litigation surfaced this period (confirm with IHA/FSSA before locking the July 1 posture).
Second, two IHCP bulletins issued May 28 (caught after the prior brief): BT202685 implements the federal payer-of-last-resort prohibition - members aged 65-and-4-months who are Medicare-eligible but unenrolled get a one-time notice on/after June 1, and effective October 1 Medicaid stops covering and reimbursing their Part D–eligible prescriptions, with go-forward recoupment, making eligibility verification a clawback-prevention function.
BT202684 (DUR Board, effective August 1) updates SUPDL and PA criteria; the item worth a second look is the brand-over-generic ARB flip (generic azilsartan nonpreferred while brand Edarbi is added to the Preferred Brand list), plus ticagrelor/Brilinta and bosentan/Tracleer flips - all oral retail items, low relevance to infusion lines but a Medicaid claims-routing and prescribing-prompt task. The Indiana Board of Pharmacy held a routine June 8 meeting with no policy actions affecting 340B, PBM regulation, or scope.
Ohio
Nothing material this week. H.B. 229’s PBM-licensure regime remains effective July 1, 2027; no new movement. The single-PBM (Gainwell) operation continues unchanged.
National-trend read
The state-protection wave broadened materially - Colorado and Hawaii enacted combined contract-pharmacy access and provider-reporting laws, the Illinois 340B access bill passed the Senate (while a separate Illinois bill to significantly restrict 340B savings drew strong provider pushback), and access bills are advancing in Virginia and Washington. The counter-data-point worth logging: per Times Union reporting,
New York’s 340B Prescription Drug Anti-Discrimination Act died in the Assembly despite Senate-side support - a reminder the state strategy remains uneven and manufacturers will keep exploiting state-by-state gaps. Washington’s SB 5981 (now in effect) is the leading edge because it directly bars conditioning 340B access on non-federally-required claims data - the exact mechanism Lilly and the other nine manufacturers are using (340B Report; Times Union).
Payer policy updates – Section 3
UnitedHealthcare - material, and the most consequential payer development for this profile
UHC is executing a coordinated tightening of oncology drug access across three dates. Live now: beginning June 2026, UHC redirects oncology PA requests (chemotherapy, radiation, related procedures) from the general provider portal to the Optum oncology portal, with outpatient chemotherapy requiring PA via Optum’s Cancer Guidance Program as of June 1. Then, effective August 1, select oncology medications used in maintenance or monotherapy are added to UHC’s Provider-Administered Drugs Site of Care Policy, with the site-of-care review folded into the existing PA. Then, on September 1, UHC will exclude certain injectable oncology drugs where equivalent alternatives are available. For a 340B DSH cancer center the combined effect is a vise: more PA friction routed through a vertically integrated Optum entity, steerage of maintenance infusions out of the HOPD, and formulary exclusions favoring lower-cost equivalents - each eroding both infusion margin and 340B capture. The June specialty medical injectable update also posted on schedule (UHCprovider.com).
Anthem (IN/OH), Humana, Aetna, CareSource, Medical Mutual of Ohio
No drug-level oncology, immunology, ophthalmology, or endocrinology infusion change independently verified this week. Anthem (specialty/precertification activity), Aetna (June OfficeLink), and Medical Mutual (June 1 formulary) all show June-1-era updates whose drug-level detail is portal-gated - treat these as “validate via portal/rep” items rather than confirmed changes or “nothing material.” Anthem is the payer to validate first for buy-and-bill exposure (Anthem Provider News; Aetna OfficeLink; Medical Mutual).
Section 4 - Industry Intelligence
Manufacturer data policies - the operational story of the week
Beyond the Lilly cutoff (Executive item 1), GSK became the 10th manufacturer to extend 340B claims-data requirements to in-house pharmacy dispensing (GSK and Sobi both announced recently). The biggest one for this portfolio is Amgen: per Cencora’s manufacturer-update tracker, Amgen’s claims-level data demand took effect June 1 - all covered-entity types asked to submit claims-level data for in-house and contract-pharmacy dispenses of all Amgen products, with healthcare-visit/service claims data beginning November 15, 2026.
Amgen matters disproportionately for oncology, bone-health, and supportive-care lines, and the medical-benefit data pull is the governance issue. The significance overall: Lilly’s wholesaler-cutoff mechanism - faster and harder to enjoin than litigation - is now adopted across a widening set even as Washington’s SB 5981 makes that conditioning unlawful in one state. Expect the map to fragment by state (340B Report; Cencora).
Premier / GPO prohibition - a purchasing win with real dollars
HRSA did not appeal the late-March D.C. ruling striking down its 2013 policy that barred certain 340B hospitals from using 340B or GPO discounts for initial drug inventory; the guidance is permanently vacated. The statutory GPO prohibition remains, but DSH hospitals can revert to first-purchasing new drugs through GPO accounts rather than at WAC - Premier pegged the prior policy’s cost in the millions per hospital per year. Action item: review the policies and inventory/purchasing automation implemented in response to the 2013 guidance to quantify the first-buy savings now available, under a defensible statutory interpretation and in consultation with counsel. One of the few unambiguously favorable, immediately actionable items in the brief (340B Report; Premier; McDermott Will & Schulte).
Drug Channels
No new original analysis this period - Fein reran the contract-pharmacy and specialty-pharmacy concentration pieces ahead of the June 12 DCI webinar “340B in 2026.” The freshest figures: roughly 31,500 pharmacies and ~240,000 unique contract-pharmacy/covered-entity relationships in 2026, with relationships up ~10,000 even as unique locations declined for a third straight year; five vertically integrated firms (Cigna, CVS Health, UnitedHealth Group, Walgreens, Walmart) hold a record 77% of all relationships, and the three largest specialty pharmacies - all PBM-affiliated - account for two-thirds of specialty prescription revenue. Relevant as you negotiate contract-pharmacy and specialty arrangements with counterparties who also own the PBMs and the Optum portal now adjudicating your oncology PAs (Drug Channels).
Drug shortages - oncology signal worth elevating
No clean new U.S. shortage broke in-window, but the global signal is concrete: India’s NPPA raised the ceiling price for cisplatin (to 10.89 rupees/ml from 7.26) and carboplatin (to 90.74 rupees/ml from 60.49) around June 11, citing shortage and supply disruptions of these NLEM-listed platinum agents, with treatment disrupted at India’s major oncology centers and no true substitutes. Why it belongs on the cancer-infusion dashboard despite being non-U.S.: prior U.S. cisplatin/carboplatin/methotrexate shortages were driven in part by a production halt at India-based Intas after FDA quality findings, so India-side platinum stress is a leading indicator for U.S. supply. Among the broader injectable list circulating (azacitidine, dexmedetomidine, bumetanide, anesthetics/opioids, methylprednisolone, rocuronium), azacitidine is the oncology-relevant standout; the rest reflect the chronic FDA/ASHP active list (~270 shortages) rather than clean new-this-week additions. Confirm against your own ASHP/University of Utah feed (Reuters; NPPA; ASHP).
PBM/specialty consolidation, M&A, and AI
Nothing material in the pharmacy supply chain this week. The FTC/Optum Rx antitrust matter remains in successive stays pointing toward a possible consent agreement; the notable M&A of the period was therapeutic-asset (GSK’s ~$10.6B Nuvalent acquisition adds NSCLC oncology assets) rather than supply-chain, so it doesn’t move channel economics.
